Emergent BioSolutions (EBS) Misses Q3 EPS by $2.71
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.80 --0%
Revenue Growth %: -45.6%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: -45.6%
Financial Fact:
Total other income (expense): -1.93M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of ($0.36), $2.71 worse than the analyst estimate of $2.35. Revenue for the quarter came in at $329 million versus the consensus estimate of $486.84 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Equinox Gold to redeem $172.5M in convertible notes in October
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
